Antipsychotic medication and length of stay at a psychiatric maximum-security unit in Norway (1987-2000)

Nordic Journal of Psychiatry

Volumn 60, Issue 2, 2006, Pages 132-136

  Renkel, Sabine ^a   Rasmussen, Kirsten ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Antipsychotics; High dosage; Maximum security; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE DECANOATE; PSYCHOTROPIC AGENT; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL HOSPITAL; NORWAY; POLYPHARMACY; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; VIOLENCE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOPENTHIXOL; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NORWAY; PSYCHIATRIC DEPARTMENT, HOSPITAL; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; VIOLENCE;

EID: 33646113838     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.1080/08039480600583662     Document Type: Article

References (22)

1. Linaker, OM and Thoresen, R and Figenschou, L and Solvberg, H and Refsnes, U and Jakobsen, D. (1994) Norske psykiatriske sikkerhetsenheter. Pasienter og virksomhet Tidsskr Nor Lægeforen, 114, pp. 1520-3.
2. Rasmussen, K and Levander, S. (1996) Symptoms and personality characteristics of patients in a maximum security unit Int J Law Psychiatry, 19, pp. 27-37.
3. Walsh, E and Leese, M and Taylor, P and Johnston, I and Burns, T and Creed, F and et al. (2002) Psychosis in high-security and general psychiatric services: Report from the UK700 and Special Hospitals Treatment Resistant Schizophrenia groups Br J Psychiatry, 180, pp. 351-7.
4. Harty, M-A and Shaw, J and Thomas, S and Dolan, M and Davies, L and Thornicroft, G and et al. (2004) The security, clinical and social needs of patients in high security psychiatric hospitals in England J Forensic Psychiatry Psychol, 15, pp. 208-21.
5. Rasmussen, K and Levander, S. (2002) Schizophrenia and violence Tidsskr Nor Lægeforen, 122, pp. 2303-5.
6. Norwegian Board of Health (Helsetilsynet). Schizofreni: Kliniske retningslinjer for utredning og behandling. In: Statens helsetilsyns utredningsserie; 2000:9. Helsetilsynet, Pb. 8128 Dep, 0032Oslo, Norway. www.helsetilsynet.no
7. American Psychiatric Association (APA). Treatment Recommendations for patients with schizophrenia, Part A. Am J Psychiatry 2004;161. Suppl 2:1-56.
8. Tavernor, R and Swinton, M and Tavernor, S. (2000) High-dose antipsychotic medication in maximum security. J Forensic Psychiatry, 11, pp. 36-48.
9. Bains-Jatinder, JS and Nielssen, OB. (2003) Combining depot antipsychotics with novel antipsychotics in forensic patients Psychiatr Bull, 27, pp. 14-16.
10. Brown, CS and Lloyd, KR and Donovan, M. (2001) Trends in admissions to a regional secure unit (1983-1997) Med Sci Law, 41, pp. 35-40.
11. Butwell, M and Jamieson, E and Leese, M and Taylor, P. (2000) Trends in special (high-security) hospitals. 2: Residency and discharge episodes 1986-1995 Br J Psychiatry, 176, pp. 260-5.
12. Norwegian Pharmaceutical Product Compendium (Felleskatalogen)2004. 46. utgave. Felleskatalogen AS, Pb. 204 sentrum, 0103Oslo, Norway. www.felleskatalogen.no
13. Stubbs, JH and Haw, CM. (2001) Medication schizophrenia and the forensic multidisciplinary team. Br J Forensic Practice, 3, pp. 29-33.
14. Centorrino, F and Eakin, M and Bahk, W-M and Kelleher, JP and Goren, J and Salavtore, P and et al. (2002) Inpatient antipsychotic drug use in 1998, 1993 and 1989 Am J Psychiatry, 159, pp. 1932-4.
15. Eichelbaum, M and Evert, B. (1996) Influence of pharmacogenetics on drug disposition and response Clin Exp Pharmacol Physiol, 23, pp. 983-5.
16. Zanger, UM and Raimondo, S and Eichelbaum, M. (2004) Cytochrome P450 2D6: Overview and update on pharmacology, genetics biochemistry. Arch Pharmacol, 369, pp. 23-37.
17. Centorrino, F and Goren, JL and Hennen, J and Salvatore, P and Kelleher, JP and Baldessarini, RJ. (2004) Multiple versus single antipsychotic agents for hospitalized patients: Case-control study of risks versus benefits Am J Psychiatry, 161, pp. 700-6.
18. Leong, G-B and Silva, JA. (2003) Neuroleptic induced akathisia and violence: A review. J Forensic Sci, 48, pp. 187-9.
19. Krakowski, M-I and Kunz, M and Czobor, P and Volavka, J. (1993) Long-term high-dose neuroleptic treatment: Who gets it and why? Hosp Community Psychiatry, 44, pp. 640-4.
20. Scheller-Gilkey, G and Wooline, BJ and Cooper, I and Gay, O and Moynes, KA and Miller, AH. (2003) Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics Am J Alcohol Abuse, 29, pp. 553-66.
21. Green, AI and Tohen, MF and Hamer, RM and Strakowski, SM and Lieberman, JA and Glick, I. (2004) First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol Schizophr Res, 66, pp. 125-35.
22. Diaz, F and de-Leon, J. (2002) J Clin Psychiatry Excessive antipsychotic dosing in 2 U.S. state hospitals, 63, pp. 998-1003.